|
|
 Previous Article | Table of Contents | Next Article 
Pleiotropic effects of the CD30 ligand on CD30-expressing cells and
lymphoma cell lines
HJ Gruss, N Boiani, DE Williams, RJ Armitage, CA Smith and RG Goodwin
Immunex Research and Development Corp, Department of Biochemistry, Seattle,
WA 98101.
CD30 is a member of the tumor necrosis factor receptor superfamily. CD30
was originally described as a cell surface antigen on primary and cultured
Hodgkin's and Reed-Sternberg cells. In this study, recombinant human CD30
ligand was expressed on the surface of CV-1/EBNA cells and tested for
biologic activities on a variety of different CD30+ human lymphoma cell
lines. CD30 ligand enhanced Ig secretion of Epstein-Barr virus
(EBV)-immortalized, CD30+ lymphoblastoid B-cell lines, but not Burkitt
lymphoma lines. Recombinant CD30 ligand enhanced proliferation of
"T-cell-like" Hodgkin's disease-derived cell lines and an adult T- cell
leukemia cell line, but not "B-cell-like" Hodgkin's disease- derived cell
lines, CD30+, EBV-immortalized lymphoblastoid B-cell lines, or CD30+ and
EBV+ tumor B-cell non-Hodgkin's lymphoma cell lines. In addition, CD30
ligand mediated reduction of proliferation and viability, by induction of
cytolytic cell death, of CD30+, large-cell anaplastic lymphoma cell lines.
Two new antibodies, M44 and M67, against the CD30 antigen demonstrated
similar biologic activities to the CD30 ligand. Taken together, these data
demonstrate pleiotropic biologic activities of the CD30 ligand on different
CD30+ lymphoma cell lines and indicate that the CD30-CD30 ligand
interaction might have a pathophysiologic role in Hodgkin's and some
non-Hodgkin's lymphomas.
Volume 83,
Issue 8,
pp. 2045-2056,
04/15/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S.-Y. Nam, Y.-H. Kim, J.-S. Do, Y.-H. Choi, H.-J. Seo, H.-K. Yi, P.-H. Hwang, C.-H. Song, H.-K. Lee, J.-S. Kim, et al.
CD30 supports lung inflammation
Int. Immunol.,
February 1, 2008;
20(2):
177 - 184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Amin and R. Lai
Pathobiology of ALK+ anaplastic large-cell lymphoma
Blood,
October 1, 2007;
110(7):
2259 - 2267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nagata, T. Ise, M. Onda, K. Nakamura, M. Ho, A. Raubitschek, and I. H. Pastan
Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy
PNAS,
May 31, 2005;
102(22):
7946 - 7951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Yamada, A. D. Salama, M. Sho, N. Najafian, T. Ito, J. P. Forman, R. Kewalramani, S. Sandner, H. Harada, M. R. Clarkson, et al.
CD70 Signaling Is Critical for CD28-Independent CD8+ T Cell-Mediated Alloimmune Responses In Vivo
J. Immunol.,
February 1, 2005;
174(3):
1357 - 1364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. I. Berro, G. A. Perry, and D. K. Agrawal
Increased Expression and Activation of CD30 Induce Apoptosis in Human Blood Eosinophils
J. Immunol.,
August 1, 2004;
173(3):
2174 - 2183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Nijsten, C. Curiel-Lewandrowski, and M. E. Kadin
Lymphomatoid Papulosis in Children: A Retrospective Cohort Study of 35 Cases
Arch Dermatol,
March 1, 2004;
140(3):
306 - 312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Borchmann, J. F. Treml, H. Hansen, C. Gottstein, R. Schnell, O. Staak, H.-f. Zhang, T. Davis, T. Keler, V. Diehl, et al.
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma
Blood,
November 15, 2003;
102(10):
3737 - 3742.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Younes and M. E. Kadin
Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy
J. Clin. Oncol.,
September 15, 2003;
21(18):
3526 - 3534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Francisco, C. G. Cerveny, D. L. Meyer, B. J. Mixan, K. Klussman, D. F. Chace, S. X. Rejniak, K. A. Gordon, R. DeBlanc, B. E. Toki, et al.
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
Blood,
August 15, 2003;
102(4):
1458 - 1465.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Willers, R. Dummer, W. Kempf, T. Kundig, G. Burg, and M. E. Kadin
Proliferation of CD30+ T-Helper 2 Lymphoma Cells Can Be Inhibited by CD30 Receptor Cross-Linking with Recombinant CD30 Ligand
Clin. Cancer Res.,
July 1, 2003;
9(7):
2744 - 2754.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nishikori, Y. Maesako, C. Ueda, M. Kurata, T. Uchiyama, and H. Ohno
High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease
Blood,
April 1, 2003;
101(7):
2789 - 2796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. Wahl, K. Klussman, J. D. Thompson, J. H. Chen, L. V. Francisco, G. Risdon, D. F. Chace, C. B. Siegall, and J. A. Francisco
The Anti-CD30 Monoclonal Antibody SGN-30 Promotes Growth Arrest and DNA Fragmentation in Vitro and Affects Antitumor Activity in Models of Hodgkin's Disease
Cancer Res.,
July 1, 2002;
62(13):
3736 - 3742.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Szocinski, A. R. Khaled, J. Hixon, D. Halverson, S. Funakoshi, W. C. Fanslow, A. Boyd, D. D. Taub, S. K. Durum, C. B. Siegall, et al.
Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax
Blood,
June 17, 2002;
100(1):
217 - 223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. F. Skinnider and T. W. Mak
The role of cytokines in classical Hodgkin lymphoma
Blood,
May 29, 2002;
99(12):
4283 - 4297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Yamada, A. D. Salama, and M. H. Sayegh
The Role of Novel T Cell Costimulatory Pathways in Autoimmunity and Transplantation
J. Am. Soc. Nephrol.,
February 1, 2002;
13(2):
559 - 575.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Aldinucci, D. Poletto, A. Gloghini, P. Nanni, M. Degan, T. Perin, P. Ceolin, F. M. Rossi, V. Gattei, A. Carbone, et al.
Expression of Functional Interleukin-3 Receptors on Hodgkin and Reed-Sternberg Cells
Am. J. Pathol.,
February 1, 2002;
160(2):
585 - 596.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Vinante, A. Rigo, M. T. Scupoli, and G. Pizzolo
CD30 triggering by agonistic antibodies regulates CXCR4 expression and CXCL12 chemotactic activity in the cell line L540
Blood,
January 1, 2002;
99(1):
52 - 60.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Levi, W. M. Pfeifer, M. E. Kadin, S. S. Mir, B. W. M. Richter, and C. S. Duckett
CD30-activation-mediated growth inhibition of anaplastic large-cell lymphoma cell lines: apoptosis or cell-cycle arrest?
Blood,
September 1, 2001;
98(5):
1630 - 1632.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. P. Hansen, S. Dietrich, T. Kisseleva, T. Mokros, R. Mentlein, H. H. Lange, G. Murphy, and H. Lemke
CD30 Shedding from Karpas 299 Lymphoma Cells Is Mediated by TNF-{alpha}-Converting Enzyme
J. Immunol.,
December 15, 2000;
165(12):
6703 - 6709.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Muta, L. H. Boise, L. Fang, and E. R. Podack
CD30 Signals Integrate Expression of Cytotoxic Effector Molecules, Lymphocyte Trafficking Signals, and Signals for Proliferation and Apoptosis
J. Immunol.,
November 1, 2000;
165(9):
5105 - 5111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Kadin
Regulation of CD30 Antigen Expression and Its Potential Significance for Human Disease
Am. J. Pathol.,
May 1, 2000;
156(5):
1479 - 1484.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Croager, A. M. Gout, and L. J. Abraham
Involvement of Sp1 and Microsatellite Repressor Sequences in the Transcriptional Control of the Human CD30 Gene
Am. J. Pathol.,
May 1, 2000;
156(5):
1723 - 1731.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Gerli, C. Pitzalis, O. Bistoni, B. Falini, V. Costantini, A. Russano, and C. Lunardi
CD30+ T Cells in Rheumatoid Synovitis: Mechanisms of Recruitment and Functional Role
J. Immunol.,
April 15, 2000;
164(8):
4399 - 4407.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Horie, V. Gattei, K. Ito, S. Imajo-Ohmi, T. Tange, J. Miyauchi, A. Pinto, M. Degan, A. De Iuliis, F. Tassan Mazzocco, et al.
Frequent Expression of the Variant CD30 in Human Malignant Myeloid and Lymphoid Neoplasms
Am. J. Pathol.,
December 1, 1999;
155(6):
2029 - 2041.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mori, C. Manuelli, N. Pimpinelli, C. Mavilia, E. Maggi, M. Santucci, B. Bianchi, P. Cappugi, B. Giannotti, and M.E. Kadin
CD30-CD30 Ligand Interaction in Primary Cutaneous CD30+ T-Cell Lymphomas: A Clue to the Pathophysiology of Clinical Regression
Blood,
November 1, 1999;
94(9):
3077 - 3083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Pfeifer, E. Levi, T. Petrogiannis-Haliotis, L. Lehmann, Z. Wang, and M. E. Kadin
A Murine Xenograft Model for Human CD30+ Anaplastic Large Cell Lymphoma : Successful Growth Inhibition with an Anti-CD30 Antibody (HeFi-1)
Am. J. Pathol.,
October 1, 1999;
155(4):
1353 - 1359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chantry, P. Romagnani, C. J. Raport, C. L. Wood, A. Epp, S. Romagnani, and P. W. Gray
Macrophage-Derived Chemokine Is Localized to Thymic Medullary Epithelial Cells and Is a Chemoattractant for CD3+, CD4+, CD8low Thymocytes
Blood,
September 15, 1999;
94(6):
1890 - 1898.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Chiarle, A. Podda, G. Prolla, E. R. Podack, G. J. Thorbecke, and G. Inghirami
CD30 Overexpression Enhances Negative Selection in the Thymus and Mediates Programmed Cell Death Via a Bcl-2-Sensitive Pathway
J. Immunol.,
July 1, 1999;
163(1):
194 - 205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Vinante, A. Rigo, E. Papini, M. A. Cassatella, and G. Pizzolo
Heparin-Binding Epidermal Growth Factor-Like Growth Factor/Diphtheria Toxin Receptor Expression by Acute Myeloid Leukemia Cells
Blood,
March 1, 1999;
93(5):
1715 - 1723.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Romagnani, F. Annunziato, R. Manetti, C. Mavilia, L. Lasagni, C. Manuelli, G. B. Vannelli, V. Vanini, E. Maggi, C. Pupilli, et al.
High CD30 Ligand Expression by Epithelial Cells and Hassal's Corpuscles in the Medulla of Human Thymus
Blood,
May 1, 1998;
91(9):
3323 - 3332.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Gilfillan, P. J. Noel, E. R. Podack, S. L. Reiner, and C. B. Thompson
Expression of the Costimulatory Receptor CD30 Is Regulated by Both CD28 and Cytokines
J. Immunol.,
March 1, 1998;
160(5):
2180 - 2187.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Chicheportiche, P. R. Bourdon, H. Xu, Y.-M. Hsu, H. Scott, C. Hession, I. Garcia, and J. L. Browning
TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family That Weakly Induces Apoptosis
J. Biol. Chem.,
December 19, 1997;
272(51):
32401 - 32410.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. U. Kuefer, A. T. Look, K. Pulford, F. G. Behm, P. K. Pattengale, D. Y. Mason, and S. W. Morris
Retrovirus-Mediated Gene Transfer of NPM-ALK Causes Lymphoid Malignancy in Mice
Blood,
October 15, 1997;
90(8):
2901 - 2910.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Funakoshi, A. Hirano, M. Beckwith, O. Asai, G. Jorgensen, Z.-g. Tian, J. L. Hornick, P. Hu, L. A. Khawli, A. L. Epstein, et al.
Antitumor Effects of Nonconjugated Murine Lym-2 and Human-Mouse Chimeric CLL-1 Monoclonal Antibodies Against Various Human Lymphoma Cell Lines In Vitro and In Vivo
Blood,
October 15, 1997;
90(8):
3160 - 3166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S. Kwon, K. B. Tan, J. Ni, K. K. Kim, Y.-J. Kim, S. Wang, R. Gentz, G.-L. Yu, J. Harrop, S. D. Lyn, et al.
A Newly Identified Member of the Tumor Necrosis Factor Receptor Superfamily with a Wide Tissue Distribution and Involvement in Lymphocyte Activation
J. Biol. Chem.,
May 30, 1997;
272(22):
14272 - 14276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Y. Lee, S. Y. Lee, and Y. Choi
TRAF-interacting Protein (TRIP): A Novel Component of the Tumor Necrosis Factor Receptor (TNFR)- and CD30-TRAF Signaling Complexes That Inhibits TRAF2-mediated NF-kappa B Activation
J. Exp. Med.,
April 7, 1997;
185(7):
1275 - 1286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Gattei, M. Degan, A. Gloghini, A. De Iuliis, S. Improta, F. M. Rossi, D. Aldinucci, V. Perin, D. Serraino, R. Babare, et al.
CD30 Ligand Is Frequently Expressed in Human Hematopoietic Malignancies of Myeloid and Lymphoid Origin
Blood,
March 15, 1997;
89(6):
2048 - 2059.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Aizawa, H. Nakano, T. Ishida, R. Horie, M. Nagai, K. Ito, H. Yagita, K. Okumura, J. Inoue, and T. Watanabe
Tumor Necrosis Factor Receptor-associated Factor (TRAF) 5and TRAF2 Are Involved in CD30-mediated NFkappa B Activation
J. Biol. Chem.,
January 24, 1997;
272(4):
2042 - 2045.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ansieau, I. Scheffrahn, G. Mosialos, H. Brand, J. Duyster, K. Kaye, J. Harada, B. Dougall, G. Hubinger, E. Kieff, et al.
Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation
PNAS,
November 26, 1996;
93(24):
14053 - 14058.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Gedrich, M. C. Gilfillan, C. S. Duckett, J. L. Van Dongen, and C. B. Thompson
CD30 Contains Two Binding Sites with Different Specificities for Members of the Tumor Necrosis Factor Receptor-associated Factor Family of Signal Transducing Proteins
J. Biol. Chem.,
May 31, 1996;
271(22):
12852 - 12858.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
